CA
VYNT

Cornerstone Advisory’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Cornerstone Advisory’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed – – 850
2021
Q4 		$0 Buy
+3
New +$31 ﹤0.01% 867

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JSC
Jackson Square Capital San Francisco, California $719M AUM 144.18% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Cornerstone Advisory's VYNT Position: Q1 2022 in Review

Cornerstone Advisory sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2022, closing a stake of 3 shares.

Cornerstone Advisory first reported a position in VYNT in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 23 funds tracked by Wall St. Rank hold VYNT as of Q1 2022.

  • Cornerstone Advisory reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Cornerstone Advisory sold 3 Vyant Bio, Inc. Common Stock shares in Q1 2022.
  • Cornerstone Advisory first reported a position in Vyant Bio, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Cornerstone Advisory's Vyant Bio, Inc. Common Stock position peaked at $0 in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.